Consort Medical increases its 2016 interim dividend by 5%

DividendMax Ltd.

Consort Medical increases its 2016 interim dividend by 5%

Revenues increase from £53.6m to £135.5m following Aesica acquisition and good organic growth

Good organic revenue growth in both Bespak with YOY growth of 5.4%; Aesica sequential CC growth of 2.3%

Operating leverage in organic EBIT growth: Bespak YOY growth of 13.1%; Aesica  sequential CC growth of 23.7%, with operating margin expansion to 6.2%

Adjusted basic EPS was slightly lower due to increase in shares in issue and finance costs following Aesica acquisition - revenue expected to be second half weighted

Interim dividend increased by 5.0% reflecting Board's confidence in the Group's prospects

Statutory PBT and EPS were lower as a result of special costs associated with Aesica integration actions

Further Net Debt reduction from £99.2m to £95.3m driven by strong cash flow from operations

Companies mentioned